PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Aflibercept - Wet age-related macular degeneration

PAD Profile : Aflibercept - Wet age-related macular degeneration Important

Keywords :
Wet AMD
Brand Names Include :
Eylea
Important Information :
Aflibercept 2mg (biosimilar when available) remains a first line treatment option (alongside ranibizumab biosimilar). Aflibercept 8mg can be used in those patients that have not responded sufficiently to the 2mg treat and extend protocols and that aflibercept 8mg will be used no more frequently than every 8 weeks in line with the licence

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 March 2025
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Aflibercept 8mg Intravitreal Injection

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the use of aflibercept 8mg intravitreal injection.

Aflibercept 2mg (biosimilar when available) remains a first line treatment option (alongside ranibizumab biosimilar).

Aflibercept 8mg can be used in those patients that have not responded sufficiently to the 2mg treat and extend protocols and that aflibercept 8mg will be used no more frequently than every 8 weeks in line with the licence

02 November 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a Wet Age Related Macular Degeneration (wet-AMD) treatment pathway attached below for information.

PLEASE NOTE: The most cost-effective anti-VEGF treatment is biosimilar ranibizumab which will be counted as a ‘free switch’ for patients where monthly injections is clinically appropriate.

06 July 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee approve the increased access to THREE switches for existing NICE approved anti-VEGF treatments to optimise response.
N.B Surrey Heartlands Integrated Care System Area Prescribing Committee DO NOT SUPPORT dose intensification (injections every 4 weeks) of aflibercept, as per change in licence since NICE guidance was published

Blueteq forms for initiation and continuation will be completed by retinal specialists in secondary care.

03 December 2014
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN supports the use of both aflibercept and ranibizumab as treatment options for wet AMD in patients who meet the specified NICE criteria (NICE TA 294 criteria for aflibercept and NICE TA 155 criteria for ranibizumab).

Associated BNF Codes

11. Eye
11.08.02. Ocular diagnostic & peri-operative prepn & photodynamic tt
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More